skip nav
National Prevention Information Network
Search Help
Other Searches: Search Organizations | Search Materials | Search Campaign Resources | Search Funding
español
Share Share this page on Twitter Share this page on Facebook Share this page on LinkedIn View more options to share this page E-mail this page to a colleague Print this page


<< Back

News

Japanese HCV-Infected Patients Met SVR with Daclatasvir, Asunaprevir

Abstract
Healio reported on a phase 3 trial of two antiviral drugs for treating chronic hepatitis C virus (HCV) genotype 1b infection. In a multiclinical trial, Japanese researchers tested dual therapy with daclatasvir and asunaprevir to treat 222 patients (median age 62.5 years; 65.3 percent women) with chronic HCV 1b who were not successful with previous therapies. The researchers separated participants into two groups, with 135 individuals forming the interferon-ineligible/intolerant group and 87 nonresponders. Participants received 60 milligrams (mg) daclatasvir once daily and 100 mg asunaprevir twice a day for 24 weeks. Results show that 87.4 percent of participants in the interferon-ineligible/intolerant group achieved sustained virologic response (SVR) at 24 weeks and 89.6 percent completed therapy. In the nonresponder group, 80.5 percent experienced SVR and 83.9 percent completed treatment. Of each group, 14 patients dropped out due to adverse effects, lack of efficacy, or at personal request; 5.9 percent of all patients experienced serious adverse effects. The researchers concluded that the 24-week ribavirin-free all-oral treatment using daclatasvir and asunaprevir showed high rates of SVR in these participants with HCV genotype 1b. The full report, “Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection,” was published in the journal Hepatology (2014; 59(6): 2083–2091; doi: 10.1002/hep.27113).
Source
http://www.healio.com
Date of Publication
06/04/2014
Article Type
General media
Article Category
Medical News

Disclaimer: NPIN provides this information as a public service only. The views and information provided about the materials, funding opportunities, and organizations do not necessarily state or reflect those of the U.S. Department of Health and Human Services, CDC, or NPIN.

cdcnpin.org News Record #63094

<< Back

CDCNPIN.org

Contact Us
About Us
HIV Content Notice
Privacy Policy
Policies & Disclaimers
Site Index
Help Using the CDC NPIN Web Site

CDC NPIN Searches

Search Organizations
Search Materials
Search Funding Opportunities
Search Campaign Resources
Help Using the CDC NPIN Searches

CDC NPIN Resources

hivtest.cdc.gov
m.hivtest.cdc.gov
findtbresources.org
STD Awareness Microsite
findstdtest.org
AIDS Gov Logo and Link CDC Logo and Link